Project Details
Description
Transfer in after proposal was submitted
| Acronym | CardioReGenix |
|---|---|
| Status | Finished |
| Effective start/end date | 1/01/2019 → 31/12/2023 |
Collaborative partners
- King's College London
- Free University of Brussels (Collaborating partner) (lead)
- University of Eastern Finland (Collaborating partner)
- A2F Associates Limited (Collaborating partner)
- Medizinische Hochschule Hanover (Collaborating partner)
- University of Edinburgh (Collaborating partner)
- VU University Medical Center (Collaborating partner)
- Batavia Biosciences B.V. (Collaborating partner)
- Finvector Vision Therapies Oy (Collaborating partner)
- Cardior Pharmaceuticals GmbH (Collaborating partner)
- ASPHALION S.L. (Collaborating partner)
- Public health department in Kuopio, Finland (Collaborating partner)
- University of Kiel (Collaborating partner)
Funding
- EC European Commission: £12,317,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.